Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Indian Laburnum Pod contains anthraquinone glycosides and quercetin that inhibit digestive enzymes including α-glucuronidase by 60.66% while supporting hepatic detoxification pathways. The pods demonstrate measurable reductions in liver enzymes SGOT, SGPT, and alkaline phosphatase in preclinical studies.
Reported Benefits (Provisional)
Origin & History
Indian Laburnum Pod (Cassia fistula), also known as Golden Shower tree, is native to the tropical and subtropical regions of the Indian subcontinent and Southeast Asia, including India, Sri Lanka, Thailand, and Myanmar. Its pods are highly valued in traditional medicine for their significant role in digestive cleansing and detoxification.
Research Narrative (Provisional)
Numerous studies, including pharmacological and preclinical investigations, support Indian Laburnum Pod's traditional uses, confirming its laxative, antimicrobial, hepatoprotective, and anti-inflammatory effects. Research highlights the role of anthraquinones and other phytochemicals in its therapeutic actions.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals: Anthraquinones (rhein, emodin, sennosides), flavonoids, tannins, polyphenolic acids. - Sugars: Natural sugars. - Vitamins: Trace amounts of Vitamin C. - Minerals: Trace amounts of calcium, magnesium.
Reported Mechanism (Provisional)
The pods' anthraquinone glycosides and quercetin work through enzyme inhibition, particularly targeting α-glucuronidase with 60.66% inhibitory activity, along with β-glucuronidase, α-glucosidase, and α-tyrosinase. Quercetin specifically upregulates IFN-γ and Th-2 gene expression, modulating NK cell function for enhanced immune response. Additional compounds including emodin and chrysophanic acid support hepatoprotective mechanisms by reducing liver enzyme markers.
Clinical Narrative (Provisional)
Preclinical studies demonstrate dose-dependent reductions in liver enzymes including SGOT, SGPT, AST, ALT, and alkaline phosphatase, with concurrent increases in total protein levels. One controlled study in rats showed significant antibody titer elevation compared to controls, indicating measurable immunomodulatory effects. However, human clinical trials are limited, and most evidence stems from pharmacological and preclinical investigations rather than large-scale human studies. The evidence base, while promising, requires additional human clinical validation.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.